AGP Executive Report
Last update: 8 hours agoObesity Drug Update: AstraZeneca reported encouraging Phase 2 results for its once-daily oral weight-loss pill elecoglipron, with the highest dose group averaging 10.5% weight loss after 26 weeks versus 0.6% on placebo, in a trial that included participants from Taiwan. Fertility & Growth: A Taiwan-based 12-year follow-up of over 21,000 children found IVF and other fertility-treatment conceptions did not appear to harm growth in the womb-to-childhood pathway the way earlier worries suggested, shifting attention to broader factors. Pediatric Endocrine Guidance: The Endocrine Society is set to release a new clinical practice guideline on central precocious puberty at ENDO 2026, building on prior Taiwan-linked research on sweeteners and early puberty risk. Drug Safety in Taiwan: Taiwan’s TFDA ordered a recall of two batches of Kremezin 500 mg tablets for chronic kidney disease after quality issues tied to residual ethanol testing methods; no adverse events were reported. Blood Supply Alert: Taiwan Blood Service Foundation says type O reserves are at 2.6 days and type A at 3.3 days, both in critical shortage territory, urging donations ahead of weekends. Local Health Policy: Control Yuan urged stronger protections for foreign interns in hospitality after findings including passport confiscation and missing social insurance coverage. Road Safety: Police reported suspected drug-impaired driving in fatal crashes in Taichung and Taoyuan, with ketamine and amphetamine flagged in preliminary tests.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.